All In Biotech

Drug Trial Radar · NCT00487435

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Open-Label Extension, Single-Arm, Flexible-Dosing, Phase 3 Trial With CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain

Last checked: Nov 19, 2026Latest source record: May 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,166

Actual

Start

Jun 2007

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Grünenthal GmbH
First posted
Jun 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the long-term safety profile of Tapentadol (CG5503) extended release (ER) at dosages ranging from 100 to 250 mg twice a day in treating patients with moderate to severe chronic pain over a period of 1 year. The study will also assess dosage requirements over the long term; characterize adverse events and tolerability, sleep quality, and potential symptoms of withdrawal; characterize pain intensity scores and overall impression of change; and characterize patient-related health outcomes.

Conditions

  • Pain
  • Osteoarthritis
  • Low Back Pain

Interventions

  • Tapentadol (CG5503) Extended Release (ER)Drug

    100, 150, 200, 250 mg oral tablet twice daily for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Treatment-emergent Adverse Events (TEAE)Time frame: 52 weeks

Locations

148 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Hoover, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Carmichael, California

  • Site not named

    Encinitas, California

  • Site not named

    Fresno, California

  • Site not named

    Huntington Park, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Los Gatos, California

  • Site not named

    Pico Rivera, California

  • Site not named

    Pismo Beach, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Upland, California

  • Site not named

    Westlake Village, California

  • Site not named

    Stamford, Connecticut

  • Site not named

    Trumbull, Connecticut

  • Site not named

    Chiefland, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Hallandale, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Oldsmar, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Tamarac, Florida

  • Site not named

    Tampa, Florida

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.